ZNTL Stock - Zentalis Pharmaceuticals, Inc.
Unlock GoAI Insights for ZNTL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $67.42M | N/A | N/A | N/A | N/A |
| Gross Profit | $67.42M | N/A | N/A | N/A | N/A |
| Gross Margin | 100.0% | N/A | N/A | N/A | N/A |
| Operating Income | $-191,194,000 | $-299,509,000 | $-227,287,000 | $-216,542,000 | $-118,787,000 |
| Net Income | $-165,839,000 | $-292,191,000 | $-236,806,000 | $-158,725,000 | $-117,841,000 |
| Net Margin | -246.0% | N/A | N/A | N/A | N/A |
| EPS | $-2.33 | $-4.47 | $-4.48 | $-3.72 | $-2.87 |
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 12th 2024 | Wedbush | Upgrade | Neutral | $4 |
| June 20th 2024 | UBS | Downgrade | Neutral | $5← $28 |
| June 18th 2024 | Jefferies | Downgrade | Hold | $6← $42 |
| June 18th 2024 | Morgan Stanley | Downgrade | Equal Weight | $8← $38 |
| June 18th 2024 | Wedbush | Downgrade | Underperform | $4← $15 |
| June 18th 2024 | Wells Fargo | Downgrade | Equal Weight | - |
| November 8th 2023 | Wedbush | Downgrade | Neutral | $12← $38 |
| November 7th 2023 | Leerink Partners | Downgrade | Market Perform | $15 |
| July 12th 2022 | Cowen | Initiation | Outperform | - |
| April 6th 2022 | Wells Fargo | Initiation | Overweight | $67 |
Earnings History & Surprises
ZNTLEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 25, 2026 | $-0.41 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.49 | $-0.37 | +24.5% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $-0.56 | $-0.37 | +33.9% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-0.67 | $-0.67 | 0.0% | = MET |
Q1 2025 | Mar 26, 2025 | $-0.75 | $-0.66 | +12.0% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.92 | $-0.56 | +39.1% | ✓ BEAT |
Q3 2024 | Aug 9, 2024 | $-0.83 | $-1.24 | -49.4% | ✗ MISS |
Q2 2024 | May 7, 2024 | $-0.77 | $0.14 | +118.2% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | $-0.92 | $-0.83 | +9.8% | ✓ BEAT |
Q4 2023 | Nov 6, 2023 | $-1.01 | $-0.79 | +21.8% | ✓ BEAT |
Q3 2023 | Aug 9, 2023 | $-1.06 | $-1.85 | -74.5% | ✗ MISS |
Q2 2023 | May 10, 2023 | $-0.96 | $-1.07 | -11.5% | ✗ MISS |
Q1 2023 | Mar 1, 2023 | $-1.09 | $-0.92 | +15.6% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-1.15 | $-0.96 | +16.5% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-1.21 | $-1.34 | -10.7% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-1.20 | $-1.31 | -9.2% | ✗ MISS |
Q1 2022 | Feb 24, 2022 | $-1.34 | $-1.11 | +17.2% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-1.31 | $-0.09 | +93.1% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $-1.14 | $-1.34 | -17.5% | ✗ MISS |
Q2 2021 | May 17, 2021 | $-0.96 | $-1.24 | -29.2% | ✗ MISS |
Latest News
Zentalis Pharmaceuticals Enters Stock Purchase Agreement With Matrix; To Repurchase 7.5M Shares At $1.33 Each
📈 PositiveMorgan Stanley Maintains Equal-Weight on Zentalis Pharma, Lowers Price Target to $4
📉 NegativeZentalis Pharma Q3 EPS $(0.37) Beats $(0.48) Estimate
📈 PositiveZentalis Pharmaceuticals Announces Four Abstracts On Its Wee1 Inhibitor, Azenosertib, Have Been Accepted For Poster Presentations At The AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics October 22–26, 2025, In Boston, Massachusetts.
📈 PositiveFrequently Asked Questions about ZNTL
What is ZNTL's current stock price?
What is the analyst price target for ZNTL?
What sector is Zentalis Pharmaceuticals, Inc. in?
What is ZNTL's market cap?
Does ZNTL pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ZNTL for comparison